Related Experiment Video
Updated: Sep 28, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations
Umit Yasar1, Eleni Aklillu, Roberto Canaparo
1Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sewden. uyasar@hacettepe.edu.tr
Objective:
CYP2C9 is a polymorphic gene with at least six known allelic variants (CYP2C9*1 to *6). CYP2C9*5 has been recently described in African-Americans. The lower activity of CYP2C9*5 encoded enzyme than *1 has been reported for the S-warfarin 7-hydroxylation in vitro. The aim of the present study was to develop an assay for the analysis of this variant and to determine the frequency of this polymorphism in different ethnic populations.
Materials And Methods:
A PCR-based endonuclease digestion method, using a mismatched forward primer that introduced a recognition site for AvaII in all the CYP2C9 genotypes except CYP2C9*5, is described. DNA samples from 150 Ethiopians, 183 Tanzanians, 200 Caucasians from Sweden and 150 Orientals from Korea were screened for this variant allele.
Results And Conclusion:
The CYP2C9*5 allele was analysed using a polymerase chain reaction-based endonuclease method, and it was found in three Tanzanians (allele frequency, 0.0082) but not in Ethiopians, Caucasians or Orientals.
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Principles of Pharmacogenetics: Types of Genetic Variants
Analysis of Population Pharmacokinetic Data
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview